GlassScriptPhysician profile
Veronica Williams
NPI 1780189803
$7,835.56
in general payments reported to CMS, 2019-2025
18 companies · $4,756 in 2025
The $4,756 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2021: $279 · 2022: $1,060 · 2023: $732 · 2024: $905 · 2025: $4,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,645 · Education: $2,569 · Travel and Lodging: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,645.08 |
| Education | $2,568.73 |
| Travel and Lodging | $1,179.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,777.47 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $1,338.52 | 2024-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $578.21 | 2022-2024 | Ofev |
| Genzyme Corporation | $503.09 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $426.94 | 2021-2023 | Fasenra |
| Glaxosmithkline, LLC. | $268.22 | 2022-2023 | Trelegy Ellipta |
| Medtronic, INC. | $209.32 | 2023 | Illumisite |
| Bayer Healthcare Pharmaceuticals INC. | $131.44 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $109.00 | 2022 | |
| Novo Nordisk INC | $102.76 | 2019 | |
| Insmed, INC. | $101.59 | 2021 | |
| Merck Sharp & Dohme LLC | $86.40 | 2024 | Winrevair |
| Mallinckrodt Hospital Products INC. | $61.62 | 2022-2024 | Acthar |
| Gilead Sciences, INC. | $57.42 | 2021-2022 | |
| Liquidia Technologies, INC. | $47.90 | 2025 | Yutrepia |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $18.34 | 2023 | Prolastin-C Liquid |
| Pulmonx Corporation | $13.58 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Janssen Pharmaceuticals, INC | $3.74 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.